ImmuCell Corporation Revenue from Contract with Customer, Excluding Assessed Tax
ImmuCell Corporation (ICCC) reported Revenue from Contract with Customer, Excluding Assessed Tax of $7.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $7.19M, a 11.50% increase year-over-year.
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $10.36M, a 28.39% increase year-over-year.
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $7.63M, a 1.61% decline year-over-year.
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $5.51M, a 8.41% decline year-over-year.
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for fiscal 2025 was $27.64M, a 4.34% increase from fiscal 2024.
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for fiscal 2024 was $26.49M, a 51.64% increase from fiscal 2023.
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for fiscal 2023 was $17.47M, a 5.90% decline from fiscal 2022.
- ImmuCell Corporation revenue from contract with customer, excluding assessed tax for fiscal 2022 was $18.57M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.19M 10-Q · filed 2026-08-13 | $17.54M 10-Q · filed 2026-08-13 | $25.17M derived: sum of 3 quarters · filed 2026-08-13 | $30.68M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $10.36M 10-Q · filed 2026-05-14 | $17.98M derived: sum of 2 quarters · filed 2026-05-14 | $23.49M derived: sum of 3 quarters · filed 2026-05-14 | $29.93M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $13.13M derived: sum of 2 quarters · filed 2026-03-30 | $19.58M derived: sum of 3 quarters · filed 2026-08-13 | $27.64M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $5.51M 10-Q · filed 2025-11-13 | $11.95M derived: sum of 2 quarters · filed 2026-08-13 | $20.02M 10-Q · filed 2025-11-13 | $27.77M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $6.44M 10-Q · filed 2026-08-13 | $14.51M 10-Q · filed 2026-08-13 | $22.26M derived: sum of 3 quarters · filed 2026-08-13 | $28.27M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $8.07M 10-Q · filed 2026-05-14 | $15.82M derived: sum of 2 quarters · filed 2026-05-14 | $21.83M derived: sum of 3 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $13.76M derived: sum of 2 quarters · filed 2026-03-30 | $26.49M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $6.01M 10-Q · filed 2025-11-13 | $18.74M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.40M derived: sum of 2 quarters · filed 2024-04-01 | $17.47M 10-K · filed 2024-04-01 | ||
| 2023-09-30 | $5.40M 10-Q · filed 2023-11-13 | $17.47M 10-Q · filed 2025-11-13 | $12.38M 10-Q · filed 2023-11-13 | ||
| 2022-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $8.71M derived: sum of 2 quarters · filed 2024-04-01 | $18.57M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $4.80M 10-Q · filed 2023-11-13 | $14.66M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $5.44M derived: 10-Q 12 month − 10-Q 9 month · filed 2023-11-13 | $10.59M derived: sum of 2 quarters · filed 2023-11-13 | $19.24M 10-Q · filed 2023-11-13 | ||
| 2021-09-30 | $5.15M 10-Q · filed 2022-11-21 | $13.80M 10-Q · filed 2022-11-21 | |||
| 2020-12-31 | $15.34M 10-Q · filed 2022-11-21 | ||||
| 2018-06-30 | $3.01M 10-Q · filed 2018-08-13 | $5.90M 10-Q · filed 2018-08-13 | |||
| 2018-03-31 | $2.88M 10-Q · filed 2018-05-14 | ||||
| 2017-06-30 | $1.75M 10-Q · filed 2018-08-13 | $5.29M 10-Q · filed 2018-08-13 | |||
| 2017-03-31 | $3.54M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |